Angiogenesis inhibitors. Drug selectivity and target specificity

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Targeting tumor vasculature with anti-angiogenic therapies has emerged as a significant advancement in cancer treatment.
• Understanding the complex signaling pathways involved in tumor angiogenesis is key to developing effective therapies.

Purpose of the Study:

• To provide a comprehensive review of anti-angiogenic therapies for cancer.
• To elucidate the mechanisms of tumor angiogenesis and its interactions with the tumor microenvironment.
• To discuss the clinical outcomes, challenges, and resistance mechanisms associated with anti-angiogenic agents.

Main Methods:

• Review of preclinical and clinical studies on anti-angiogenic agents.
• Analysis of growth factor signaling pathways, including VEGF/VEGFR.
• Examination of interactions between tumor angiogenesis, hypoxia, stroma, and the tumor microenvironment.

Main Results:

• Anti-angiogenic agents, including VEGF/VEGFR inhibitors, direct angiogenesis inhibitors, and vascular disrupting agents, have shown clinical efficacy in various tumors.
• Tumor angiogenesis is a complex process influenced by hypoxia, stroma, and the tumor microenvironment.
• Emergence of resistance is a significant limitation, necessitating further research into combination therapies and novel strategies.

Conclusions:

• Anti-angiogenic therapies represent a major breakthrough in cancer treatment by targeting tumor vasculature.
• Despite clinical successes, challenges remain, including understanding resistance mechanisms and optimizing therapeutic strategies.
• Further research into novel anti-angiogenic molecules and combination approaches is crucial for improving patient outcomes.